Unapproved research chemicalHuman evidenceProhibited in sport

CJC-1295

Also referred to as CJC-1295 DAC, Modified GRF (1-29), Sermorelin analogue

Early-phase human pharmacokinetic work exists. The DAC and non-DAC forms behave very differently and are routinely conflated in commercial material.

Molecule class: GHRH analogue, supplied with or without a drug-affinity complex
Category: GH axis
Last evidence review: 2026-08-23

Compare this compound Check interactions Solution calculator

Human studies

Animal / in vitro

Graded claims

—

Participants

Mechanism

What is being studied

GHRH receptor agonist. The DAC variant binds serum albumin, substantially extending the half-life and producing sustained rather than pulsatile GH elevation.

Evidence

Claims, graded individually

Each statement below carries its own evidence level, its own confidence rating, and its own account of what remains unestablished. A compound does not have a single grade.

GH-Axis Research

CPreliminaryLow confidenceHuman evidence

CJC-1295 has been reported to produce sustained elevation of GH and IGF-1 concentrations in early-phase human work.

What is not established

No outcome trials. Sustained non-pulsatile GH elevation departs from normal physiology and its consequences are not established. DAC and non-DAC forms differ materially.

Supporting sources (1)

Pharmacokinetic studyHumanIdentifier pending verification

CJC-1295 pharmacokinetics and sustained GH/IGF-1 elevation

Teichman SL, Neale A, Lawrence B, et al. · Journal of Clinical Endocrinology & Metabolism (and related) · 2006

Population: Healthy adult volunteers
Endpoint: GH and IGF-1 concentration over time
Route: Subcutaneous
Quantity as reported: Single and multiple ascending doses in early-phase work
Frequency: Single and repeated dosing

Result. Sustained elevation of GH and IGF-1 concentrations was reported following administration in early-phase human work.

Adverse events. Injection-site reactions and flushing reported in early-phase work.

Limitations. Early-phase pharmacodynamic work only. No outcome trials. The DAC and non-DAC forms differ materially and are frequently conflated in non-scientific sources.

Search PubMed for this literature →

Last evidence review: 2026-08-23

Human evidence

1 human study catalogued

Human and non-human evidence are kept strictly separate. They are never pooled, averaged, or presented as a single body of support.

Pharmacokinetic studyHumanIdentifier pending verification

CJC-1295 pharmacokinetics and sustained GH/IGF-1 elevation

Teichman SL, Neale A, Lawrence B, et al. · Journal of Clinical Endocrinology & Metabolism (and related) · 2006

Population: Healthy adult volunteers
Endpoint: GH and IGF-1 concentration over time
Route: Subcutaneous
Quantity as reported: Single and multiple ascending doses in early-phase work
Frequency: Single and repeated dosing

Result. Sustained elevation of GH and IGF-1 concentrations was reported following administration in early-phase human work.

Adverse events. Injection-site reactions and flushing reported in early-phase work.

Limitations. Early-phase pharmacodynamic work only. No outcome trials. The DAC and non-DAC forms differ materially and are frequently conflated in non-scientific sources.

Search PubMed for this literature →

Pharmacology

Reported parameters

Half-life

7.0 days

The DAC form is reported at roughly 6–8 days. The non-DAC form (modified GRF 1-29) is on the order of 30 minutes. Treating these as the same compound is a common and material error.

Visualise this half-life →

Routes studied

Subcutaneous

Evidence from one route does not transfer to another. Topical, oral, and injected administration can produce entirely different exposure from the same quantity.

Regulatory status

Not approved for human use. Prohibited in sport.

Storage as documented

No approved labelling exists.

Safety

Signals reported in the literature

This lists what has been reported. It is not a complete safety profile, and for several compounds in this catalogue no systematic safety surveillance exists at all.

Sustained, non-pulsatile GH elevation departs from normal physiology and its long-term consequences are not established
Injection-site reactions and flushing reported in early-phase work

Interactions

Register entries involving this compound

ipamorelin ↔ cjc-1295

The premise is mechanistically coherent, but the specific combination has not been evaluated in an adequate human study. Commercial availability of a blend is not evidence.

Limitations. This is one of the most commonly assumed combinations in this category and one of the least supported by evidence.

Open the full interaction explorer →

Limitations

What the evidence cannot tell you

Given as much prominence as the findings, because for most compounds in this category it is the more important half.

Early-phase pharmacodynamic work only; no outcome trials
DAC and non-DAC forms must not be compared or substituted

Reference

Evidence grading key

AStrong

Multiple high-quality human trials, or strong systematic-review or meta-analytic evidence.

BModerate

Human controlled evidence exists, but replication or sample size is limited.

CPreliminary

Small human studies, observational evidence, or early-phase clinical work.

DPreclinical

Predominantly animal or in-vitro evidence. No adequate human outcome data.

EMechanistic

Biological plausibility or mechanistic reasoning without adequate outcome evidence.

XInsufficient / conflicting

Evidence is absent, irreconcilable, or too weak to support any directional statement.

Other compounds studied in the same research areas

Tesamorelin

A GHRH analogue with phase 3 randomised evidence in one specific population: adults with HIV-associated abdominal lipodystrophy.

Ipamorelin

A GH secretagogue reported as more selective than earlier compounds in the class. The evidence is pharmacodynamic, not outcome-based.

Sermorelin

Historically approved in a paediatric growth-hormone-deficiency population and used diagnostically. Not studied as a wellness intervention in adults.

Hexarelin

A potent secretagogue notable for rapid desensitisation and for effects on cortisol and prolactin that ipamorelin was designed to avoid.